Operational ExpenditureManagement needs to scale back some of its planned OpEx investments given a slower top-line trajectory.
Operational RisksManagement pointed to the realization of many risks regarding the company and market, including delayed decision making, an increase in competition, and a delay in the HCA rollout.
Revenue GuidanceA combination of more competition, slowing decision-making and existing customers shifting to Augmedix's lower cost offerings is behind the company lowering its 2024 revenue guidance.